Loading...
•
Mar 31, 2021
Curis Q1 2021 Earnings Report
Curis reported financial results for Q1 2021 and provided a corporate update.
Key Takeaways
Curis reported a net loss of $9.9 million, or $0.11 per share, for the first quarter of 2021, compared to a net loss of $9.7 million, or $0.28 per share, for the same period in 2020. Revenues for the first quarter of 2021 were $2.2 million, compared to $2.7 million for the same period in 2020. As of March 31, 2021, Curis's cash, cash equivalents and investments totaled $168.4 million.
Continued momentum for pipeline of next generation targeted cancer therapies.
CA-4948 now in three clinical trials after expanding into one new study with the Phase 2 LUCAS IST for patients with lower-risk MDS.
Phase 1/2 study in R/R NHL expanded to include the combination of CA-4948 plus ibrutinib; dosing was initiated in Q1.
CA-4948 was granted Orphan Drug designation from the FDA for the treatment of AML and MDS.
Curis
Curis
Curis Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.com Forward Guidance
Curis expects that its existing cash, cash equivalents and investments should enable it to maintain its planned operations into 2024.
Positive Outlook
- Report additional clinical data at the EHA 2021 Virtual Congress from the Phase 1/2 monotherapy study of CA-4948 in patients with AML and MDS.
- Initiate dosing in the Phase 1/2 combination study of CA-4948 plus azacitidine and CA-4948 plus venetoclax in patients with R/R AML and MDS.
- Report initial data from the ongoing Phase 1/2 combination study of CA-4948 plus ibrutinib in patients with R/R NHL in the second half of 2021.
- Report initial data from the ongoing Phase 1 monotherapy study of CI-8993 for the treatment of R/R solid tumors in the second half of 2021.